{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:02:02Z","timestamp":1794279722195,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025ZNSFSC1723"],"award-info":[{"award-number":["2025ZNSFSC1723"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","award":["2025HXBH145"],"award-info":[{"award-number":["2025HXBH145"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012842","name":"Nuclear Power Institute of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012842","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["JG2024418"],"award-info":[{"award-number":["JG2024418"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118644","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:55:59Z","timestamp":1770134159000},"page":"118644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy"],"prefix":"10.1016","volume":"307","author":[{"given":"Su","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118644_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"52","key":"10.1016\/j.ejmech.2026.118644_bib2","doi-asserted-by":"crossref","first-page":"36547","DOI":"10.1074\/jbc.M109.033712","article-title":"Structures of the dual bromodomains of the p-TEFb-activating protein brd4 at atomic resolution","volume":"284","author":"Vollmuth","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118644_bib3","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1093\/nar\/gkx561","article-title":"BRD4 inhibitors block telomere elongation","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118644_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2174\/1568026620666200109114339","article-title":"Potential telomere-related pharmacological targets","volume":"20","author":"Berei","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118644_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/leu.2016.182","article-title":"Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in myc-driven tumors","volume":"31","author":"Donato","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118644_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118644_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An updated patent review of BRD4 degraders","volume":"34","author":"Ma","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118644_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","article-title":"Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation","volume":"151","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"7570","key":"10.1016\/j.ejmech.2026.118644_bib9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"7570","key":"10.1016\/j.ejmech.2026.118644_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118644_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cells12111461","article-title":"Impact of short-term (+)-JQ1 exposure on mouse aorta: unanticipated inhibition of smooth muscle contractility","volume":"12","author":"Yan","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118644_bib12","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118644_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors i-BET151 and i-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118644_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor , in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118644_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cells13171443","article-title":"Unraveling the role of bromodomain and extra-terminal proteins in human uterine leiomyosarcoma","volume":"13","author":"Yang","year":"2024","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118644_bib16","first-page":"1","article-title":"First-in-human study of TQB3617, a BET inhibitor in patients with relapsed\/refractory hematologic malignancies","volume":"42","author":"Cai","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118644_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","article-title":"Phase i study of CC-90010 , a reversible , oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-hodgkin's lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118644_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1694","article-title":"Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): updated results from a phase ib\/II study","volume":"34","author":"Villar","year":"2023","journal-title":"Ann. Oncol."},{"issue":"27","key":"10.1016\/j.ejmech.2026.118644_bib19","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118644_bib20","first-page":"1","article-title":"Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis","volume":"42","author":"Rampal","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118644_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2026.118644_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2023.108371","article-title":"Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance","volume":"244","author":"Zhu","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118644_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2023.106624","article-title":"Proteolysis targeting chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment","volume":"192","author":"Gan","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118644_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"5971","key":"10.1016\/j.ejmech.2026.118644_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"728","key":"10.1016\/j.ejmech.2026.118644_bib26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(63)91347-3","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"Yang","year":"1963","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118644_bib27","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118644_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pharmaceutics16111486","article-title":"Recent advances in peptide drug discovery: novel strategies and targeted protein degradation","volume":"16","author":"Vrbnjak","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118644_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/19420862.2024.2415333","article-title":"Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan","volume":"16","author":"Mukai","year":"2024","journal-title":"mAbs"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118644_bib30","doi-asserted-by":"crossref","first-page":"11580","DOI":"10.1021\/acs.jmedchem.4c00723","article-title":"Targeted protein degradation: current and emerging approaches for e3 ligase deconvolution","volume":"67","author":"Xiao","year":"2024","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118644_bib31","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/bph.16079","article-title":"The application of targeted protein degradation technologies to g protein - coupled receptors","volume":"181","author":"Keen","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"6241","key":"10.1016\/j.ejmech.2026.118644_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118644_bib33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"26","key":"10.1016\/j.ejmech.2026.118644_bib34","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118644_bib35","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1016\/j.bmcl.2016.09.048","article-title":"Practical synthesis of a phthalimide-based cereblon ligand to enable PROTAC development","volume":"26","author":"Lohbeck","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118644_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118644_bib37","first-page":"13","article-title":"ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118644_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118644_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejmech.2023.115924","article-title":"Discovery of (r)-4-(8-methoxy-2-methyl-1 -(1-phenylethy)-1h-imidazo[4,5-c]quinnolin-7-yl)- 3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation","volume":"263","author":"Yu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118644_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cbpa.2020.02.003","article-title":"Domain-selective targeting of BET proteins in cancer and immunological diseases","volume":"57","author":"Petretich","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118644_bib41","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118644_bib42","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.bmcl.2012.01.125","article-title":"From ApoA1 upregulation to BET family bromodomain inhibition: discovery of i-BET151","volume":"22","author":"Mirguet","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118644_bib43","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.bmcl.2012.02.041","article-title":"Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of i-BET151 (GSK1210151a)","volume":"22","author":"Seal","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"7370","key":"10.1016\/j.ejmech.2026.118644_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118644_bib45","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.1c00855","article-title":"Discovery of a novel bromodomain and extra terminal domain (BET) protein inhibitor, i-BET282e, suitable for clinical progression","volume":"64","author":"Jones","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118644_bib46","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1021\/acschembio.4c00505","article-title":"A \"goldilocks zone\" for recruiting BET proteins with bromodomain-1-selective ligands","volume":"19","author":"Mohammed","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"6489","key":"10.1016\/j.ejmech.2026.118644_bib47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118644_bib48","unstructured":"Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. In."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118644_bib49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-24-0019","article-title":"Targeting metabolic dependencies fueling the TCA cycle to circumvent therapy resistance in acute myeloid leukemia","volume":"84","author":"Boet","year":"2024","journal-title":"Cancer Res."},{"issue":"810","key":"10.1016\/j.ejmech.2026.118644_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1126\/scitranslmed.adn5400","article-title":"Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models","volume":"17","author":"Zhou","year":"2025","journal-title":"Sci. Transl. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:38:47Z","timestamp":1775482727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S0223523426000899"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118644","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118644"}}